Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.81 USD | +0.65% | -0.65% | -14.53% |
04-02 | Jennifer Baron Joins NRC Health as Its First Chief Experience Officer | CI |
02-14 | National Research Corporation Provides Earnings Guidance for 2024 | CI |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 941.4 | 1,638 | 1,080 | 1,056 | 920.5 | 971 |
Enterprise Value (EV) 1 | 967.2 | 1,661 | 1,078 | 1,030 | 918.9 | 1,003 |
P/E ratio | 34.5 x | 52.3 x | 29.5 x | 28.4 x | 29.4 x | 31.6 x |
Yield | 1.65% | 1.18% | 0.49% | 1.16% | 2.25% | 1.21% |
Capitalization / Revenue | 7.87 x | 12.8 x | 8.1 x | 7.14 x | 6.07 x | 6.54 x |
EV / Revenue | 8.08 x | 13 x | 8.09 x | 6.96 x | 6.06 x | 6.75 x |
EV / EBITDA | 23.7 x | 34.2 x | 21.7 x | 18.2 x | 17.7 x | 21.8 x |
EV / FCF | 26.6 x | 96.2 x | 56.7 x | 25.5 x | 49.4 x | 59.6 x |
FCF Yield | 3.75% | 1.04% | 1.76% | 3.92% | 2.02% | 1.68% |
Price to Book | 49.4 x | 49.8 x | 16.9 x | 11.9 x | 12.7 x | 19.6 x |
Nbr of stocks (in thousands) | 24,684 | 24,836 | 25,260 | 25,436 | 24,679 | 24,546 |
Reference price 2 | 38.14 | 65.94 | 42.75 | 41.52 | 37.30 | 39.56 |
Announcement Date | 19-03-08 | 20-03-06 | 21-03-05 | 22-03-04 | 23-03-03 | 24-02-27 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 119.7 | 128 | 133.3 | 148 | 151.6 | 148.6 |
EBITDA 1 | 40.79 | 48.57 | 49.65 | 56.76 | 51.83 | 45.98 |
EBIT 1 | 35.33 | 43.04 | 42.86 | 50.71 | 46.56 | 40.09 |
Operating Margin | 29.52% | 33.63% | 32.16% | 34.28% | 30.72% | 26.98% |
Earnings before Tax (EBT) 1 | 34.71 | 40.52 | 41.47 | 48.62 | 42.82 | 39.96 |
Net income 1 | 30.05 | 32.41 | 37.26 | 37.47 | 31.8 | 30.97 |
Net margin | 25.1% | 25.32% | 27.96% | 25.32% | 20.98% | 20.84% |
EPS 2 | 1.106 | 1.260 | 1.450 | 1.460 | 1.270 | 1.250 |
Free Cash Flow 1 | 36.31 | 17.26 | 19.02 | 40.37 | 18.59 | 16.85 |
FCF margin | 30.34% | 13.49% | 14.27% | 27.29% | 12.26% | 11.34% |
FCF Conversion (EBITDA) | 89.02% | 35.54% | 38.31% | 71.12% | 35.86% | 36.63% |
FCF Conversion (Net income) | 120.85% | 53.27% | 51.05% | 107.75% | 58.45% | 54.39% |
Dividend per Share 2 | 0.6300 | 0.7800 | 0.2100 | 0.4800 | 0.8400 | 0.4800 |
Announcement Date | 19-03-08 | 20-03-06 | 21-03-05 | 22-03-04 | 23-03-03 | 24-02-27 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | 25.7 | 23.1 | - | - | - | 32.3 |
Net Cash position 1 | - | - | 1.45 | 25.7 | 1.64 | - |
Leverage (Debt/EBITDA) | 0.6309 x | 0.4757 x | - | - | - | 0.7025 x |
Free Cash Flow 1 | 36.3 | 17.3 | 19 | 40.4 | 18.6 | 16.8 |
ROE (net income / shareholders' equity) | 55.1% | 125% | 76.7% | 50.1% | 40.4% | 51.2% |
ROA (Net income/ Total Assets) | 18.8% | 24.6% | 21.9% | 21.8% | 20.2% | 19.8% |
Assets 1 | 160.1 | 131.8 | 169.8 | 172 | 157.4 | 156.3 |
Book Value Per Share 2 | 0.7700 | 1.320 | 2.530 | 3.480 | 2.930 | 2.020 |
Cash Flow per Share 2 | 0.5300 | 0.5400 | 1.370 | 2.210 | 1.020 | 0.2700 |
Capex 1 | 5.97 | 4.66 | 3.98 | 5.51 | 9.84 | 15.8 |
Capex / Sales | 4.99% | 3.64% | 2.99% | 3.73% | 6.49% | 10.62% |
Announcement Date | 19-03-08 | 20-03-06 | 21-03-05 | 22-03-04 | 23-03-03 | 24-02-27 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-14.53% | 807M | |
+10.55% | 67.6B | |
+11.64% | 18.21B | |
+21.03% | 13.41B | |
+9.40% | 13.37B | |
+16.53% | 9.94B | |
-32.90% | 5.74B | |
-10.98% | 5.57B | |
-4.09% | 4.91B | |
-4.83% | 4.87B |
- Stock Market
- Equities
- NRC Stock
- Financials National Research Corporation